Brittle Response to Levodopa as a Marker of Parkinson's Disease Phenotype Characterized by Heavy Motor and Non Motor Burden.
作者信息
Abate Filomena, Erro Roberto, Fasano Alfonso, Barone Paolo, Picillo Marina
机构信息
Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno (SA), Italy.
Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN. Division of Neurology, University of Toronto, Toronto, Canada.
出版信息
J Mov Disord. 2025 Jan;18(1):31-34. doi: 10.14802/jmd.24182. Epub 2024 Nov 11.
Abstract
摘要
相似文献
1
Brittle Response to Levodopa as a Marker of Parkinson's Disease Phenotype Characterized by Heavy Motor and Non Motor Burden.对左旋多巴的脆性反应作为以严重运动和非运动负担为特征的帕金森病表型的标志物。
J Mov Disord. 2025 Jan;18(1):31-34. doi: 10.14802/jmd.24182. Epub 2024 Nov 11.
2
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.帕金森病运动症状的自然史和左旋多巴的长期反应。
Brain. 2020 Aug 1;143(8):2490-2501. doi: 10.1093/brain/awaa181.
3
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson's Disease.卡比多巴/左旋多巴肠内悬浮液与脑深部电刺激对医疗保险按服务收费的晚期帕金森病患者减轻服药负担的比较效果
Neurol Ther. 2023 Apr;12(2):459-478. doi: 10.1007/s40120-022-00433-w. Epub 2023 Jan 18.
4
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.罗替高汀透皮贴剂联合肠内左旋多巴输注治疗帕金森病 1 年的耐受性：1 种 24 小时治疗选择。
J Neural Transm (Vienna). 2022 Jul;129(7):889-894. doi: 10.1007/s00702-022-02506-4. Epub 2022 May 3.
5
The role of istradefylline in the Parkinson's disease armamentarium.依曲替酯在帕金森病治疗中的作用。
Expert Opin Pharmacother. 2023 May;24(7):863-871. doi: 10.1080/14656566.2023.2201374. Epub 2023 Apr 18.
6
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.帕金森病患者左旋多巴相关运动并发症的药物治疗
CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005.
7
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.XINDI 研究：一项随机、III 期临床试验，评估了沙芬酰胺作为左旋多巴添加治疗对中国有运动波动的帕金森病患者的疗效和安全性。
CNS Drugs. 2022 Nov;36(11):1217-1227. doi: 10.1007/s40263-022-00958-6. Epub 2022 Nov 8.
8
GOCOVRI (amantadine) extended-release capsules in Parkinson's disease.用于帕金森病的 GOCOVRI（金刚烷胺）缓释胶囊。
Neurodegener Dis Manag. 2022 Feb;12(1):15-28. doi: 10.2217/nmt-2021-0028. Epub 2021 Dec 17.
9
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.普拉克索与罗匹尼罗治疗帕金森病的比较。
Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039.
10
Cabergoline for levodopa-induced complications in Parkinson's disease.卡麦角林治疗帕金森病左旋多巴诱导的并发症
Cochrane Database Syst Rev. 2001;2001(1):CD001518. doi: 10.1002/14651858.CD001518.
本文引用的文献
1
Disparities in Access to Deep Brain Stimulation for Parkinson's Disease and Proposed Interventions: A Literature Review.《帕金森病深部脑刺激治疗机会不均等及干预措施研究：文献综述》
Stereotact Funct Neurosurg. 2024;102(3):179-194. doi: 10.1159/000538748. Epub 2024 May 2.
2
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies.帕金森病女性患者未满足的需求：差距与争议
Mov Disord. 2022 Mar;37(3):444-455. doi: 10.1002/mds.28921. Epub 2022 Jan 20.
3
Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease.左旋多巴与丘脑下刺激后帕金森病多巴胺激动剂的比较。
Mov Disord. 2021 Mar;36(3):672-680. doi: 10.1002/mds.28382. Epub 2020 Nov 9.
4
Analysis of factors associated with brittle response in patients with Parkinson's disease.分析帕金森病患者脆性反应相关因素。
Ann Clin Transl Neurol. 2020 May;7(5):677-682. doi: 10.1002/acn3.51028. Epub 2020 Apr 30.
5
Malevich's Shoulder and Dystonia.马列维奇的肩部与肌张力障碍
Mov Disord Clin Pract. 2014 Sep 1;1(3):273. doi: 10.1002/mdc3.12060. eCollection 2014 Sep.
6
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.帕金森病亚型的临床标准：生物标志物和纵向进展。
Brain. 2017 Jul 1;140(7):1959-1976. doi: 10.1093/brain/awx118.
7
The relevance of gender in Parkinson's disease: a review.帕金森病中性别因素的相关性：综述
J Neurol. 2017 Aug;264(8):1583-1607. doi: 10.1007/s00415-016-8384-9. Epub 2017 Jan 4.
8
Gender and non motor fluctuations in Parkinson's disease: A prospective study.帕金森病中的性别与非运动波动：一项前瞻性研究。
Parkinsonism Relat Disord. 2016 Jun;27:89-92. doi: 10.1016/j.parkreldis.2016.04.001. Epub 2016 Apr 4.
9
The "brittle response" to Parkinson's disease medications: characterization and response to deep brain stimulation.帕金森病药物治疗的“脆性反应”：特征及对深部脑刺激的反应
PLoS One. 2014 Apr 14;9(4):e94856. doi: 10.1371/journal.pone.0094856. eCollection 2014.
10
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients.早期帕金森病的异质性：对未经治疗的新诊断患者的聚类分析。
PLoS One. 2013 Aug 1;8(8):e70244. doi: 10.1371/journal.pone.0070244. Print 2013.
Zotero 插件